Technical Analysis for TYME - Tyme Technologies, Inc.

Grade Last Price % Change Price Change
grade D 1.73 -2.26% -0.04
TYME closed down 2.26 percent on Friday, September 20, 2019, on 2.4 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical TYME trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Expansion Breakout Bullish Swing Setup -2.26%
Outside Day Range Expansion 3.59%
Wide Bands Range Expansion 3.59%
Overbought Stochastic Strength 3.59%
NR7 Range Contraction 8.13%
Wide Bands Range Expansion 8.13%
Overbought Stochastic Strength 8.13%
Upper Bollinger Band Walk Strength 8.13%

Older signals for TYME ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company's another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company's therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.
Biopharmaceutical Cancer Life Sciences Drug Development Cancer Therapeutics Millennium Pharmaceuticals Takeda Pharmaceutical Company
Is TYME a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 4.64
52 Week Low 0.92
Average Volume 473,214
200-Day Moving Average 1.9299
50-Day Moving Average 1.2196
20-Day Moving Average 1.378
10-Day Moving Average 1.586
Average True Range 0.1124
ADX 46.22
+DI 37.9654
-DI 6.0109
Chandelier Exit (Long, 3 ATRs ) 1.5528
Chandelier Exit (Short, 3 ATRs ) 1.3872
Upper Bollinger Band 1.8322
Lower Bollinger Band 0.9238
Percent B (%b) 0.89
BandWidth 65.921626
MACD Line 0.156
MACD Signal Line 0.1143
MACD Histogram 0.0417
Fundamentals Value
Market Cap 154.53 Million
Num Shares 89.3 Million
EPS -0.14
Price-to-Earnings (P/E) Ratio -12.36
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.94
Resistance 3 (R3) 1.94 1.86 1.91
Resistance 2 (R2) 1.86 1.81 1.87 1.89
Resistance 1 (R1) 1.80 1.78 1.76 1.80 1.88
Pivot Point 1.72 1.72 1.71 1.73 1.72
Support 1 (S1) 1.66 1.67 1.62 1.66 1.58
Support 2 (S2) 1.58 1.64 1.59 1.57
Support 3 (S3) 1.52 1.58 1.56
Support 4 (S4) 1.52